Skip to main content
OpenTrials
Completed

NCT Number: NCT03074045

LCS16 vs. COC User Satisfaction and Tolerability Study

To evaluate user satisfaction in young nulliparous and parous women (18-29 years of age [inclusive]), using LCS16 compared to a COC over a period of 12 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception

Age range

18 year–29 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Altai State Medical University, Barnaul, Russia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject has signed and dated the Informed Consent Form (ICF).
  • The subject is healthy when requesting contraception.
  • The subject is between 18 - 29 years of age (inclusive) at the time of signing the ICF.
  • The subject has normal or clinically insignificant cervical smear for oncocytology (i.e. Pap test) not requiring further follow up (a cervical smear has to be taken at the Screening Visit [Visit 1] or a normal result has to have been documented within the previous 6 months).
  • The subject has a history of regular (i.e., endogenous cyclicity without hormonal contraceptive use) cyclic menstrual periods (length of cycle 21 - 35 days), as confirmed by the subject.
  • The subject is willing and able to attend the scheduled study visits and to comply with the study procedures.

Exclusion criteria

  • Pregnancy or current lactation (less than 6 weeks postpartum or since abortion before the Screening Visit)
  • Infected abortion or postpartum endometritis within 3 months prior to the Screening Visit.
  • Chronic, daily use of drugs that may increase serum potassium levels.
  • Undiagnosed abnormal genital bleeding.
  • Acute cervicitis or vaginitis (until successfully treated).
  • Lower urinary tract infection (until successfully treated).
  • Acute or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections.
  • Congenital or acquired uterine anomaly including fibroids, in the opinion of the investigator, which would interfere with insertion and/or retention of the intrauterine system (i.e., if they distort the uterine cavity).
  • Cervical neoplasia, uterine or cervical malignancy, or sex hormone-dependent tumors.
  • History of migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia.

Treatment and study plan

Levonorgestrel (Kyleena, BAY86-5028)

Drug

Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years

Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)

Drug

COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months

Primary outcomes

  1. Overall satisfaction rate

    Time frame: 12 months

    5-point Likert item

    • Very satisfied
    • Satisfied
    • Neither satisfied nor dissatisfied
    • Dissatisfied
    • Very dissatisfied

Secondary outcomes

  1. Number of adverse events

    Time frame: Up to 5 years

    at 1, 6 and 12 months for all subjects during the comparative part of the study.

    at the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.

  2. Discontinuation rates

    Time frame: Up to 5 years

    at 1, 6 and 12 months for all subjects during the comparative part of the study.

    at the end of Year 2, Year 3, Year 4 and Year 5 only for subjects, who elect to enter the LCS16 extension phase.

  3. Bleeding pattern

    Time frame: Up to 12 months

    Only during the comparative part of the study

  4. User satisfaction and bleeding questionnaire

    Time frame: Up to 12 months

    At 6 and 12 months after the start of study treatment (or at early termination for those subjects discontinuing the study before completion of the 12 months) for all subjects during the comparative part of the study.

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison to a Combined Oral Contraceptive (COC) Containing 30 μg Ethinyl Estradiol and 3 mg Drospirenone (Yarina®) in Young Nulliparous and Parous Women (18 - 29 Years) Over 12 Months of Use (With an Option for Extended Use of LCS16 for up to 5 Years)

Important dates

Study start
2017
Primary completion
2018
Study completion
2022
First posted
Mar 8, 2017
Registry last updated
Jun 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.